Publications by authors named "Joanna Hilt"
Article Synopsis
- SB4 (Benepali, Brenzys) is a biosimilar to etanercept, showing similar efficacy and safety in a 52-week study of patients with rheumatoid arthritis (RA), followed by a 48-week open-label extension.
- In the extension phase, 126 patients continued with SB4 and 119 switched from etanercept to SB4, with American College of Rheumatology (ACR) response rates remaining high and comparable between the groups.
- Overall, SB4 was effective and well-tolerated over 2 years, with no notable risks identified in switching from etanercept to SB4.
Tumor necrosis factor (TNF alpha) plays a key role in the pathogenesis of rheumatoid arthritis (RA), where both cell-mediated and humoral immune responses contribute to the destruction of cartilage and inflammation of synovium. This article presents genetics, properties and mechanisms of action of TNF alpha in RA. In addition, results of experimental and clinical studies are summarized, showing that treatment with antagonists against TNF alpha proved to be beneficial to the patients with RA by modifying the course of disease, slowing its progress and reducing its symptoms.
View Article and Find Full Text PDF